Abstract : NAD(P)H-quinone oxidoreductase-1 (NQO1) is a down-stream target gene of nuclear factor erythroid 2-related factor 2 (Nrf2), and performs diverse biological functions. Recently, NQO1 is recognized as an effective gene for the cytotoxic inserts with its diverse biological functions, which is focused on antioxidant properties. The aim of present study was to assess the impact of NQO1 knockdown on cytoprotection-related protein expression in cisplatin cytotoxicity by using small interfering (si) RNA targeted on NQO1 gene. Cytotoxicity of cisplatin on ACHN cells was assessed in a dose-and time-dependent manner after siScramble or siNQO1 treatment. After cisplatin treatment, cells were subjected to cell viability assay, western-blot analysis, and immunofluorescence study. The cell viability was decreased in the siNQO1 cells (50%) than the siScramble cells (70%) after 24 h of cisplatin (20 µM) treatment. Moreover, cytoprotection-related protein expressions were markedly suppressed in the siNQO1 cells after cisplatin treatment. The expression of Nrf2 and Klotho were decreased by 20% and 40%, respectively, of that in siScramble cells. Nrf2 and Klotho activation were also decreased in cisplatin treated siNQO1 cells, confirmed by cytoplasm-tonuclear translocation. Our findings demonstrate that the increased cisplatin-induced cytotoxicity was accompanied by suppressed Nrf2 activation and Klotho expression in siNQO1 cells.
Introduction
Cisplatin is a highly effective anticancer drug, used in the treatment of various types of solid tumors. Despite its clinical effectiveness, the application of cisplatin is limited, owing to its severe side effects such as dose-related nephrotoxicity [4] . Cisplatin induces mitochondrial damage and in turn, generates oxidative stress that could aggravate cisplatin cytotoxicity [18] . Several studies have focused on reducing oxidative stress to relieve cisplatin-induced cytotoxicity [2, 11, 15] NAD(P)H-quinone oxidoreductase-1 (NQO1) is a flavoenzyme that has various biological functions. In general, NQO1 is recognized as a detoxification enzyme with its reactive quinone reducing activity and known to play an antioxidant role through endogenous quinone reduction which generates hydroquinones that exerts antioxidant properties [26, 27] . Moreover, NQO1 found to stabilize p53 proteins, which regulates various proteins involved in protection from oxidative stress [24] . The expression of NQO1 is highly inducible and regulated by nuclear factor erythroid 2-related factor 2 (Nrf2) [25] . Nioi et al. [22] reported that promoter region of NQO1 gene contains an Nrf2-binding consensus regulatory sequence, antioxidant response element (ARE), which implicates in NQO1 promoter activity. Nrf2/ARE is a major defense mechanism pathway against oxidative stress in cellular system, which regulates protein expression that involves in the reactive oxidants eradication [21] .
Previously, several studies have explored protective role of NQO1 by assessing its antioxidant properties [14, 23] . NQO1 was found to be highly expressed in systems that demand high levels of defense against antioxidants [31] . Furthermore, knockdown of NQO1 was found to exacerbate cisplatin-induced cytotoxicity [12] . Aggravated cell damage under NQO1 deleted conditions might result from the absence of NQO1 function, and this absence could affect NQO1-related cytoprotective signals. In the present study, we explored whether NQO1 silencing affects cytoprotection related protein expressions including Nrf2, hemoxigenase1 (HO-1), and Klotho in cisplatin treated adenocarcinoma (ACHN) cells by using small interfering (si) RNA treatment. 
Materials and Methods
Cell culture and NQO1 silencing The human kidney ACHN cells were from the American Type Culture Collection (USA). Cells were cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin (Gibco-BRL, USA) at 37 o C under 5% CO 2 . For NQO1 silencing, siRNA was used to ACHN cells. Cells were seeded (1 × 10 5 cells/mL) in 6-well plates and incubated with scrambled siControl or siRNA targeting human NQO1 (5'-AAACCAGCCUUUCAGAAUGGCUGGC-3', 20 nM; Invitrogen, USA) and hyperfectant reagent (Qiagen, USA) for 30 h. After silencing, cells were further treated with serial concentration of cisplatin (0, 5 10, and 20 µM for 24 h) for western-blot analysis. For a time-dependent assessment in change, cells were harvested at 0, 1, 3, 6, 12, and 24 h after cisplatin (20 µM) treatment.
Cell viability assay
After siScramble or siNQO1 treatment, cells (1 × 10 4 cells/ mL) were seeded in 96-well plates for cell viability assay. The day after, 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed by using cell viability assay kit (EZ-cytox; DaeilLab Service, Korea) according to the manufacturer's protocol.
Western blot analysis
Cells were lysed in lysis buffer (20 mM Tris-HCl pH 8 with protease inhibitor cocktail) and electrophoresed in a 10-15% SDS-polyacrylamide gel. The proteins were transferred onto nitrocellulose membrane in a Semi-Dry Transfer system (Bio-Rad Laboratories, USA). The membranes were blocked with 5% dry milk with 20% TWEEN-20 (TBS-T). After blocking, the membranes were incubated with antiNrf2 (1 : 1,000 dilution; Abcam, USA), anti-NQO1 (1 : 1,000 dilution; Santa Cruz Biotechnology, USA), anti-HO-1 (1 : 1,000 dilution; Stressgen Biotechnologies, USA), anti-klotho (1 : 1,000 dilution; Abcam), or β-actin (1 : 3,000; Abcam) antibodies, followed by a horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG antibody. Horseradish peroxidase activity was detected using an enhanced chemiluminescence detection kit (Amersham ECL Western Blotting Detection Kit; GE Healthcare, UK). Band intensities (n = 3) were quantified by an ImageJ program (US National Institutes of Health, USA) and normalized to β-actin.
Immunofluorescence study ACHN cells (8 × 10
3 /well) were seeded on glass chamber slides and NQO1 silencing was achieved as described above. After cisplatin treatment (20 µM for 30 min), the cells were fixed with alcohol and washed. After blocking with 3% bovine serum albumin, the cells were incubated anti-Nrf2 (1 : 100 dilution; Abcam) overnight. After washing and blocking, the cells were incubated with goat anti-rabbit Alexa Fluor 594 (Life Technologies, USA) for 60 min and mounted with ProLong Gold Antifade Mountant with DAPI (4',6-diamidino-2-phenylindole) (Life Technologies). The cells were viewed using an Olympus IX-71 microscope (Olympus, Japan) and images were captured using Olympus DP Controller software. Merged images were achieved using ZEN 2009 software (Carl Zeiss Microscopy, Germany).
Statistical analysis
The data were expressed as the means ± SD. The data were analyzed using one way analysis of variance (ANOVA) or non-parametric Kruskal-Wallis test, as appropriate, followed by a Tukey's multiple comparison test or Mann-Whitney U test. P values less than 0.05 were considered statistically significant.
Results

Cisplatin-induced cytotoxicity in NQO1-knocked down ACHN cells
In this study, we investigated whether deletion of NQO1 affects cytoprotection-related protein expression in cisplatin cytotoxicity, using in vitro assay adapted to silencing method. First, we tested the MTT assay for assessing the cisplatin induced cytotoxicity on ACHN cells (1 × 10 5 cells/mL) in the presence or absence of NQO1. High cisplatin activation has been reported to occur one day treated with cisplatin in this earlier study [30] . Therefore, here we treated the cells with cisplatin for 24 h. Furthermore, we explored changes in cytotoxicity upon cisplatin treatment for 48 h. Our results revealed that cisplatin treatment reduced the viability of both siScramble and siNQO1 cells in a time-dependent manner. Moreover, as expected, siNQO1 cells showed significantly lower viability (p < 0.05) than did the siScramble cells 12, 24, and 48 h after cisplatin treatment (Fig. 1) . Figure 2 shows that NQO1 was knocked-down in these cells. As expected, the expression of NQO1 was enhanced upon cisplatin treatment in the siScramble cells. On the other hand, cisplatin-induced Nrf2 expression was relatively decreased in the siNQO1 cells (1 × 10 5 cells/mL) than in the siScramble cells. Additionally, cisplatin-induced HO-1 expression was almost four times higher in the siNQO1 cells than in the siScramble cells. In contrast, although Klotho expression was initially increased upon cisplatin treatment in the siScramble cells, it later decreased in a dose-dependent manner (p < 0.05).
The expressions of NQO1, Nrf2, and Klotho were gradually enhanced upon cisplatin treatment (20 µM) in the siScramble cells (Fig. 3) . In the siNQO1 cells, similar to the dosedependent results, Nrf2 expression was relatively lower than that in the siScramble cells, while the expression of Klotho was remarkably lower than that in the NQO1-intact siScramble cells at all the time points. In addition, HO-1 expression was generally higher in the siNQO1 cells than in the siScramble cells upon cisplatin treatment.
Nuclear translocation of Nrf2 and Klotho cisplatintreated ACHN cells under NQO1-knocked down
Immunofluorescence experiments were performed to assess Nrf2 and Klotho expression in cisplatin-treated ACHN (Fig. 4) . After cisplatin treatment, however, Nrf2 expression was focalized in the nuclear regions, which indicates nuclear translocation of Nrf2. However, cisplatintreated siNQO1 cells showed relatively reduced nuclear translocation of Nrf2 than did the cisplatin-treated siScramble cells with higher cytoplasmic Nrf2 expression. Meanwhile, Klotho expression was focalized in both the nuclear and cytoplasmic regions. Cisplatin-treated siNQO1 cells showed relatively reduced expression of Klotho in the nuclear and cytoplasmic regions than did the cisplatin-treated siScramble cells with higher Klotho expression.
Discussion
In the present study, a part from direct antioxidant property of NQO1, we explored impact of NQO1 silencing on cytoprotection-related signal expression in cisplatin cytotoxicity. At first, we confirmed cytoprotective effect of NQO1 by assessing cisplatin-induced cell viability decrement under NQO1 absence condition. As expected, deletion of NQO1 gene intensified cisplatin-induced cell viability decrement that supports protective role of NQO1 against cytotoxic insults.
After confirming exacerbated cytotoxicity in siNQO1 cells, we further assessed changes in cytoprotection-related proteins including Nrf2, HO-1, and Klotho after cisplatin treatment. Nrf2 is an up-stream transcription factor of NQO1 that regulates various antioxidant protein expression. Activation of Nrf2 induces the expression of detoxification enzymes as well as enzymes for antioxidants synthesis, which participate in oxidative damage suppression [17] . In addition, several studies reported that the Nrf2 suppression impairs NQO1 expression [1, 10] . Hu et al. [8] demonstrated that basal NQO1 expression was repressed in tissues obtained from Nrf2-knockout mice and stress conditions failed to induce NQO1 expression; this supports involvement of Nrf2 in NQO1 expression [16] . Interestingly, in this study, deletion of NQO1, the down-stream target gene of Nrf2, resulted in reduced cisplatin-induced Nrf2 expression in a dose dependent manner. Furthermore, effect of NQO1 silencing on Nrf2 activation was confirmed by immunofluorescence study. Under unstressed condition, Nrf2 is constitutively expressed in the cell cytoplasm and degraded, while under oxidative stress, Nrf2 is translocated directly to the nucleus where it binds to a DNA promoter and initiates transcription of antioxidative genes and their protein synthesis [3] . In this study, NQO1 silencing reduced cisplatin-induced Nrf2 activation in ACHN cells as well as decreased the nuclear translocation of Nrf2.
HO-1 is an enzyme that controls heme catabolism and its induction is known to be associated with protection against oxidative stress [5] . HO-1 and NQO1 are generally recognized as similar down-stream target genes of Nrf2. Previously, Yeligar et al. [29] have demonstrated that ethanolinduced oxidative stress enhances the expressions of both HO-1 and NQO1. However, although Nrf2 is involved in activation of both enzymes, the signal transduction pathways for HO-1 induction is different from that of the NQO1. Further, HO-1 showed different transcription pattern when compared to that shown by NQO1 upon HIF-1α silencing. In the present study, although Nrf2 expression was reduced by NQO1 knock-down, HO-1 showed enhanced expression under NQO1 silenced condition. This might be due to the different signaling pathways involveed in HO-1 and NQO1 transcription.
We also assessed changes in Klotho expression under NQO1 deleted condition. Klotho is regarded as an anti-aging protein that is expressed in multiple tissues, especially in the kidney [13] . Multiple age-related disorders were reported in Klotho-knockout mice, and these pathologies were reversed by induction of Klotho expression [19] . Furthermore, previous researches have revealed that Klotho has anti-oxidative, anti-apoptosis, and anti-fibrosis activities [9, 20, 28] . Interestingly, in the present study, Klotho was negatively regulated by NQO1 silencing in cisplatin treated ACHN cells. After cisplatin treatment, Klotho expression was evidently suppressed by NQO1 silencing with a time-and concentrationdependent manner. Recently, pathophysiologic role of Klotho in acute and chronic renal injury has been reported, and Klotho has emerged as a novel target for the renoprotection [6, 7] . Aggravated cisplatin-induced cytotoxicity in siNQO1 ACHN cells, observed in the present study, might be related to reduce Klotho expression, implicated in renoprotection.
In the present study, we found the intensified cytotoxicity and altered cytoprotection-related signal expressions in the ACHN cells under NQO1 deleted condition. NQO1 deleted cells also showed decreases of cisplatin-induced Nrf2 expression and nuclear translocation together with a significantly suppression of Klotho expression. Although further mechanistic studies are needed, taken together, these results indicate that compromised cytoprotection upon NQO1 silencing is associated with altered cytoprotection-related signaling pathway.
